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Abstract
One of the suggested ways of the use of nanoparticles in virology implies their association
with and subsequent deactivation of virions. The conditions determining the efficiency of
this approach in vivo are now not clear. Herein, I propose the first kinetic model describ-
ing the corresponding processes and clarifying these conditions. My analysis indicates that
nanoparticles can decrease concentration of infected cells by a factor of one order of mag-
nitude, but this decrease itself (without feedback of the immune system) is insufficient for
full eradication of infection. It can, however, induce delay in the progress of infection, and
this delay can help to form sufficient feedback of the immune system.
Keywords Nanoparticles · Viral infection · Inhibition · Association · Kinetic model
With rapid development of nanoscience during the last decade, one can observe numer-
ous efforts to use nanoparticles (NPs) in various applications related to medicine [1]. In
particular, NPs have potential to be efficient nanocarriers for delivery of drugs of the new
generation including those based on mRNAs and miRNAs [2]. In diagnostics, NPs can
be employed e.g as contrast agents for X-ray imaging [3]. Plasmonic NPs can be used in
hyperthermia therapy [4]. In virology, different nanomaterial strategies for virus targeting
include (i) nanomaterial-enhanced viral replication inhibitors, (ii) virus-binding NPs, (iii)
cell membrane decoys binding to virions and preventing viral infection of cells, (iv) viral
membrane inhibitors disrupting membrane-enveloped virions, (v) extracorporeal blood fil-
ters removing circulating virions from the bloodstream to reduce disease burden, and (vi)
biomimetic nanoparticle vaccines mimicking the multivalent presentation of antigens on
virion surfaces and eliciting improved immune response [5] (Fig. 1; see also Refs. [6, 7]).
In all these areas belonging to biochemical engineering in general and in those related to
virology in particular, the physico-chemical scientific background is still limited especially
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Fig. 1 Schematic illustration of various strategies of the use of nanomaterials for virus targeting includ-
ing (i) nanomaterial-enhanced viral replication inhibitors, (ii) virus-binding NPs, (iii) cell membrane decoys
binding to virions and preventing viral infection of cells, (iv) viral membrane inhibitors disrupting membrane-
enveloped virions, (v) extracorporeal blood filters removing circulating virions from the bloodstream to
reduce disease burden, and (vi) biomimetic nanoparticle vaccines mimicking the multivalent presentation
of antigens on virion surfaces and eliciting improved immune response (adapted from Ref. [5]; copyright
Wiley-VCH GmbH; reproduced with permission)
from the perspective of applications in vivo, and the progress requires understanding and
overcoming a series of physiological and technical obstacles including, e.g., opsonization
and nonspecific protein adsorption (e.g., protein corona formation), nonspecific uptake by
cells and organs comprising the immune system, etc. [1].
The interplay of various processes occurring with participation of NPs in vivo may be
far from trivial, and one of the ways to clarify what may happen under these conditions is
based on the use of kinetic models. Following this line, I focus herein on NPs in virology
or, more specifically, on item (ii) in the paragraph above, i.e., on virus-binding NPs. Con-
cerning this item, one can mention as-synthesized NPs without or with additional surface
functionalization (e.g., water-dispersible benzoxazine monomer-derived and glycyrrhizic
acid-derived carbon dots [8, 9]; these and other NPs are reviewed in [5, 6]), biologically
inspired spiky nanostructures (e.g., Ref. [10]; reviewed in [5]), and multivalent NPs fabri-
cated from biomaterials (e.g., mucin-inspired NPs [11]). In these experimental studies (Refs.
[8–11]), NPs were shown to inhibit infection of cells. Although the mechanism of this effect
can be debated, the experiments appear to indicate that the association of NPs with virions
inhibits virion binding to the cells. These (Refs. [8–11]) and other related experimental stud-
ies (reviewed in [5–7]) are primarily academic, the corresponding antiviral activities have
been characterized in vitro, and the results obtained, despite their importance, do not reflect
in full extent the features occurring in vivo. In the latter case, the two key general already
mentioned complications are related to nonspecific binding of NPs to various biological
components and formation of the protein corona around NPs [1, 5] (the latter is reviewed
e.g. in [12, 13]).
Below, I present the first kinetic model allowing one to clarify the specifics of the kinetics
of interaction of NPs with virions in vivo and to identify the factors influencing the effi-
ciency of the effect of NPs on viral infection at least at the level of kinetic criteria. Although
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the model is aimed at virus-binding NPs [item (ii)], it is applicable to viral membrane
inhibitors [item (iv)] as well.
For my analysis, I use and extend the generic temporal kinetic model (see, e.g., the review
by Handel et al. [14]) operating with the concentrations of uninfected cells, U , infected
cells, I , and free virions, V , within individual patients or, more specifically, in a specific
organ of a body. The original version of this model includes three temporal kinetic equations
for these populations,
dU/dt = w − rUV − γU, (1)
dI/dt = rUV − κI, (2)
dV/dt = pI − αrUV − kV, (3)
where w is the rate of production of uninfected cells, r is the infection rate constant (α ≥ 1
is the dimensionless coefficient taking into account that the number of virions absorbed by
a cell per an infection act is larger than one), p is the rate constant of production of virions,
and γ , κ , and k are the death and/or clearance (e.g., via convective transport) rate constants.
The model defined by (1)–(3) is especially suitable for describing the initial phase of
infection because it does not include the feedback between infection and the immune sys-
tem. It can be applicable in various situations. In particular, depending on the specifics of
infection, the concentrations employed in the model can be defined as number of species
per unit volume of the tissue under consideration, unit surface area (e.g., of the epithelium),
and/or unit length of blood channels. The parameters, w, r , and p, should be measured in
the corresponding units. For the presentation below, these details of the definition of these
concentrations and parameters do not matter because the final results will be illustrated by
using dimensionless combinations of rate constants (without or with time, t).
The analysis of the initial phase of infection is a reasonable first step. The later phase
including the feedback between infection and the immune system is also of interest, but
its description is complicated by the complexity of the immune system which operates at
differen levels (reviewed in [15]). Focusing at the initial phase of infection, I will consider
that the uninfected cells are in excess and the change of their concentration is negligible.
In this case, (1) is irrelevant, whereas (2) and (3) can be simplified by setting U = const
and including U into r , i.e., by replacing rU by r . Equation (3) can be simplified taking
into account that αrUV becomes mathematically similar to kV (provided U = const), and
accordingly the former can be included into the latter, i.e., αrU + k can be replaced by k.
With this specification, (2) and (3) are reduced to
dI/dt = rV − κI, (4)
dV/dt = pI − kV . (5)
These equations are linear and can be solved analytically. To articulate the specifics of the
initial phase of infection, one can notice that typically the time scale characterizing the
virion dynamics is shorter than that characterizing the dynamics of infected cells (because
k > κ [14]), and accordingly (5) can be solved in the steady-state approximation, i.e., one
can set V = pI/k. Substituting this expression into (4) yields
dI/dt = (pr/k − κ)I, or I ∝ exp[(pr/k − κ)t]. (6)
During the initial phase of acute infection, one has pr/k > κ , and accordingly the growth
of the population of infected cells is exponential.
To scrutinize the suppression on virus infection by NPs, I consider that association of a
virion with a NP inactivates a virion and identify V with the concentration of active virions.
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In this case, the equation for V is obtained by complementing (5) by the term describing the
virion-NP association,
dV/dt = pI − kV − ηSV, (7)
where η is the association rate constant, and S is the extracellular NP concentration. The
equation for the latter concentration is as follows
dS/dt = v(t) − μS − βηSV, (8)
where v(t) the rate of the NP supply, μ is the NP deactivation and/or clearance (e.g. via con-
vective transport) rate constant, and β is the dimensionless coefficient taking into account
that the number of NPs attached to a virion or the number of virions attached to a NP may
be larger than one (in principle, this coefficient can be dropped because it does not influence
the analysis and conclusions below).
In combination with (4), (7) and (8) form a basis for my analysis. The conceptual back-
ground of these equations is simple, and the equations are simple as well. On the other
hand, the number of the corresponding rate constants is large, and their likely range is wide.
Some of the rate constants can be estimated theoretically. In the absence of a protein corona,
for example, the association of NPs and virions is expected to be limited by diffusion, and
the corresponding rate constant can be estimated by using the conventional Smoluchowski
expression, η  4πRD, whereR = R1 +R2 is the contact radius or, more specifically, the
sum of the reactant radii, and D is the sum of the reactant diffusion coefficients. The deac-
tivation of NPs may occur via their interaction with various macromolecules or membrane
receptors. The maximum rate constant of the former channel can be estimated by employ-
ing the Smoluchowski expression as well. The maximum rate constant of the latter channel
is also limited by diffusion, and the corresponding expressions are available [16]. In the
presence of a protein corona, these rate constants can be reduced. The estimates of the other
rate constants is less straightforward. Below, as already noticed, I will use a dimensionless
combinations of rate constants rather than the rate constants themselves.
To solve (4), (7), and (8), I simplify (8) by employing two reasonable assumptions. First,
I consider that as expected the timescale of the NP supply is much shorter than those char-
acterizing other processes. In this case, the rate of the NP supply can be represented as
v(t) = S◦δ(t), where S◦ is the overall NP concentration corresponding to the supply, and
δ(t) is the delta function. Second, I take into account that the contacts of NPs with the cell
membranes and extracellular macromolecules are much more frequent than those with viri-
ons and that the convective transport of NPs (if it plays a role) is rather efficient as well.
Under such conditions, μS is expected to be appreciably larger that βηSV , and accordingly
βηSV can be neglected in (8). With these simplifications, (8) yields
S = S◦ exp(−μt). (9)
Substituting this expression into (7) results in
dV/dt = pI − kV − ηS◦V exp(−μt). (10)
NPs can be efficient in suppression of infection provided they are efficient at least just
after the injection. This means that in practically important situations we can focus on the
phase when the elimination of virions occurs primarily via their association with NPs. This
phase is realized provided ηS◦ exp(−μt) ≥ k and accordingly can be observed at
t ≤ t	 ≡ [ln(ηS◦/k)]/μ. (11)
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In this case, kV can in (10) be dropped, and then, (10) can be solved by analogy with (5) in


















[exp(μt) − 1] − κt
)
. (14)
Thus, this concentrations depends on the dimensionless combination of parameters, P ≡
pr/μηS◦, and two rate constants, κ and μ.
Expression (14) for the concentration of infected cells is the main mathematical outcome
of the analysis presented. It has been obtained provided NPs are efficient in suppression of
infection at least just after the injection. Mathematically, this means that the ratio pr/μηS◦
should be much smaller than unity. In addition, the NM deactivation or clearance has been
considered to be significant. The latter means μ  κ (this condition is expected to hold
because κ is usually low [14]). Typical kinetics predicted by (14) under these conditions
are shown in Fig. 2. First, the concentration of infected cells is predicted to drop. In this
case, (pr/μηS◦)[exp(μt) − 1] can be neglected (because pr/μηS◦ 	 1), and the drop is
exponential
I (t)  I (0) exp(−κt). (15)
With extinction of active NPs, the concentration of infected cells starts, however, to increase,
i.e., the infection recovers. The latter prediction is correct provided the minimal concentra-
tion of infected cells is significant and/or the activity of the immune system remains low.
The time, t∗, corresponding to the minimal concentration is determined by the condition
exp(μt∗) = κηS◦/pr and given by
t∗ = [ln(κηS◦/pr)]/μ. (16)
The minimal concentration is accordingly as follows














Fig. 2 Population of infected
cells as a function of time after
injection of NPs, according
to (14) with
P ≡ pr/μηS◦ = 10−3, 10−4,
and 10−5 and μ = 3κ
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= 1 + ln(κk/pr)
ln(ηS◦/k)
. (18)
Expression (14) has been obtained provided κk/pr < 1 and ηS◦/k > 1, and accordingly
t∗/t	 < 1. This means that the minimal concentration of infected cells is predicted to be in
the time span where the analysis is self-consistent.
Thus, the model (14) presented indicates that the suppression of viral infection by NPs




Hypothetically, this condition can be fulfilled. Whether or not it is fulfilled in reality
depends on the specific values of the corresponding parameters. At present, the full sets of
these parameters for real infections are lacking. For this reason, I avoid further scrutiny of
this aspect.
The maximum suppression depends on P and the ratio between μ and κ . To reach appre-
ciable suppression, one should obviously decrease μ. The interaction of NPs with other
species (e.g., with extracellular proteins or cell membranes) is, however, very frequent and
can easily results in deactivation of NPs. Thus, as already noticed, one can expect that usu-
ally μ  κ . Under this condition, the concentration of infected cells can be decreased by
a factor down about one order of magnitude (Fig. 2). This decrease is appreciable, but by
itself (without feedback from the immune system) it is insufficient for full eradication of
infection. It can, however, induce delay in the progress of infection, and this delay can help
to form sufficient feedback of the immune system.
Finally, I notice that the model presented can be extended at the temporal level by includ-
ing the terms corresponding to feedback of the immune system. It can be done in different
ways (reviewed e.g. in [14, 15]). The model presented can be extended also at the spatio-
temporal level by including the terms taking blood- or lymph-mediated NP circulation (the
corresponding experimental and theoretical studies related primarily to the drug and NP
delivery to cancer tumors are now already available [1, 17, 18]).
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